Carteolol is a non-selective beta blocker used to treat glaucoma. It is administered in the form of eye drops.[citation needed]
Clinical data | |
---|---|
Trade names | Ocupress |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a601078 |
License data |
|
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 85% |
Metabolism | Liver, active with 8-hydrocarteolol |
Elimination half-life | 6–8 hours |
Excretion | Kidney (50–70%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C16H24N2O3 |
Molar mass | 292.379 g·mol−1 |
3D model (JSmol) |
|
Chirality | Racemic mixture |
| |
| |
(verify) |
Carteolol was patented in 1972 and approved for medical use in 1980.[1]
Carteolol is a beta blocker, or an antagonist of the β-adrenergic receptors.[2] It is selective for the β1-adrenergic receptor and has intrinsic sympathomimetic activity.[2] Carteolol has also been found to act as a serotonin 5-HT1A and 5-HT1B receptor antagonist in addition to being a beta blocker.[3]
Carteolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier.[2] This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects.[2]
Brand names of carteolol include Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Ocupress, Poenglaucol, Singlauc, and Teoptic.